Opendata, web and dolomites


Advancing a novel peptide-based therapeutic for pancreatic cancer

Total Cost €


EC-Contrib. €






 FIBROHALT project word cloud

Explore the words cloud of the FIBROHALT project. It provides you a very rough idea of what is the project "FIBROHALT" about.

neighbouring    pancreatic    bart    overview    enhanced    treatment    promotes    matrix    university    50    cells    treat    fibrohalt    dr    ceo    models    rate    drugs    survival    sell    patient    company    clinically    medical    de    deal    coo    peptide    2016    inventor    prognosis    80    clinical    metastasis    clear    pursuing    explanation    plan    av3    metselaar    fibrous    jai    demonstrated    cancers    fibrosis    perform    unmet    disease    median    pursue    distant    approvals    developer    mission    co    stage    form    tumor    pioneering    obtain    biopharmaceutical    diseases    entrepreneur    dismal    chemotherapy    stromal    create    devastating    prakash    position    gt    consists    stimulate    breakthrough    strategy    optimal    fda    chemotherapies    pharmaceutical    drug    grow    team    spun    add    cancer    forms    risk    efficacy    ema    barrier    twente    aggressive    regression    intensively    opportunity    stroma    reduces    prof    founder       market    join    potentially    licensing    strategies    xenograft    scientific   

Project "FIBROHALT" data sheet

The following table provides information about the project.


Organization address
address: DE HORST 2 ZUIDHORST 254
postcode: 7522 LW
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCARTEC THERAPEUTICS BV NL (ENSCHEDE) coordinator 50˙000.00


 Project objective

Pancreatic cancer is a devastating disease with a median 5-year survival rate of 3-5%. One explanation for the dismal prognosis is the failure of many chemotherapies. Pancreatic tumor cells stimulate neighbouring non-tumor cells (stromal cells) to join and grow around them. This stroma forms a fibrous matrix that promotes 1) aggressive tumor growth, 2) distant metastasis, and 3) form a barrier to chemotherapy and drug delivery. There is a high need to enhance the success of pancreatic cancer treatment by intensively pursuing strategies that target the tumor stroma. We are developing a novel peptide-based drug (AV3), that targets and reduces tumor stroma in pancreatic cancer, and potentially in other fibrosis-associated cancers. We have demonstrated that AV3 reduces fibrosis (>50%) and enhanced the efficacy of chemotherapy in clinically relevant patient-derived xenograft models (achieving up to 80% tumor regression). Thus, our novel peptide has the potential to become a breakthrough add-on to chemotherapy in the treatment of pancreatic cancer. We are a biopharmaceutical company, spun-out in 2016 by the University of Twente. Our mission is to develop novel, targeted, peptide-based drugs to treat pancreatic cancer and other fibrosis-associated cancers and diseases with high unmet medical needs. The management team consists of its pioneering scientific founder and inventor of the technology Prof. Jai Prakash (CEO) and an experienced entrepreneur and drug developer Dr. Bart Metselaar (COO). The FIBROHALT project will (1) create a clear overview of the clinical opportunity for AV3 in pancreatic cancer, 2) develop a strategy to position the drug in the pancreatic cancer market, and (3) create an optimal development strategy, including a de-risk plan for future clinical studies. We will pursue a co-development or licensing deal for AV3 with a pharmaceutical company which will perform late-stage clinical development, obtain EMA/FDA approvals, market and sell AV3.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FIBROHALT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FIBROHALT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

HAC (2019)


Read More